泛JAK抑制剂地高替尼乳膏在慢性手部湿疹16周随机IIb期试验中显示剂量反应
这项双盲IIb期剂量探索试验纳入258例对局部糖皮质激素应答不足或有禁忌的慢性手部湿疹成人患者,随机接受地高替尼乳膏1、3、8、20 mg/g或赋形剂每日两次治疗16周。IGA-CHE治疗成功率在1、3、8、20 mg/g组分别为21.2%、7.8%、36.5%、37.7%,赋形剂组为8.0%,8和20 mg/g组对比赋形剂P<0.001,并建立显著剂量反应关系(P<0.025)。地高替尼乳膏耐受性良好,多数不良事件为轻中度且被认为与治疗无关。
要点
- 地高替尼乳膏在慢性手部湿疹中显示显著剂量反应关系(IGA-CHE,P<0.025)。
- 第16周IGA-CHE治疗成功率:8 mg/g组36.5%、20 mg/g组37.7%,赋形剂组8.0%。
- 地高替尼乳膏耐受性良好,最常见不良事件为鼻咽炎、湿疹和头痛。
核心结论
- 地高替尼乳膏在慢性手部湿疹中显示出疗效方面的剂量反应关系,且耐受性良好。
研究设计与样本
- 双盲、IIb期剂量探索试验,纳入258例有近期局部糖皮质激素应答不足或禁忌的慢性手部湿疹成人患者。
- 患者按1:1:1:1:1随机分配至地高替尼乳膏1、3、8、20 mg/g或赋形剂组,每日两次治疗16周。
主要发现
- 第16周IGA-CHE治疗成功率:1 mg/g组21.2%、3 mg/g组7.8%、8 mg/g组36.5%、20 mg/g组37.7%、赋形剂组8.0%。
- 8和20 mg/g组对比赋形剂显示治疗效应(P<0.001)。
- HECSI、瘙痒和疼痛NRS评分及PaGA均有改善。
- 最常见不良事件:鼻咽炎在地高替尼组为17.3-29.4%、赋形剂组为40%;湿疹在地高替尼组为5.8-11.3%、赋形剂组为16.0%;头痛在地高替尼组为3.8-11.5%、赋形剂组为4.0%。
关键数值与推荐
- 主要终点为第16周IGA-CHE治疗成功(0分或1分且较基线改善≥2分)。
- 已建立IGA-CHE显著剂量反应关系(P<0.025)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hand eczema (CHE) is a burdensome disease, and new well-documented, safe and efficacious treatments are warranted. In a recent CHE phase IIa trial, the pan-Janus kinase (JAK) inhibitor delgocitinib in an ointment formulation was found to be efficacious and well tolerated. OBJECTIVES: This trial assessed the dose response, efficacy and safety of delgocitinib cream in CHE. METHODS: In this double-blind, phase IIb dose-ranging trial, adults with CHE and a recent history of inadequate response or contraindication to topical corticosteroids were randomized to delgocitinib cream 1, 3, 8, 20 mg g-1 or vehicle treatment twice daily for 16 weeks. The primary endpoint was the Investigator's Global Assessment for CHE (IGA-CHE) treatment success [0 (clear) or 1 (almost clear) with a ≥ two-point improvement from baseline to week 16]. Secondary endpoints were the time to IGA-CHE treatment success and changes in Hand Eczema Severity Index (HECSI); other endpoints were itch and pain numerical rating scale (NRS) scores, and Patient's Global Assessment (PaGA) at week 16. RESULTS: Patients (n = 258) were randomized 1 : 1 : 1 : 1 : 1 to delgocitinib cream 1, 3, 8, 20 mg g-1 or vehicle. A significant dose-response relationship was established for IGA-CHE (P < 0.025). IGA-CHE treatment success at week 16 was achieved in 21.2% (1 mg g-1 ), 7.8% (3 mg g-1 ), 36.5% (8 mg g-1 ), 37.7% (20 mg g-1 ) and 8.0% (vehicle) of patients. Delgocitinib 8 and 20 mg g-1 showed a treatment effect against vehicle (P < 0.001). Similarly, there were improvements in HECSI, itch and pain NRS scores, and PaGA. Delgocitinib cream was well tolerated with the majority of adverse events being mild or moderate and considered unrelated to treatment. The most frequently reported adverse events were nasopharyngitis (17.3-29.4% in delgocitinib groups vs. 40% in vehicle group), eczema (5.8-11.3% in delgocitinib groups vs. 16.0% in vehicle group) and headache (3.8-11.5% in delgocitinib groups vs. 4.0% in vehicle group). CONCLUSIONS: In this trial, delgocitinib cream showed a dose-response relationship in terms of efficacy and was well tolerated.
引用
- Worm M, Thyssen JP, Schliemann S, et al. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial. Br J Dermatol. 2022. PMID: 35084738. doi:10.1111/bjd.21037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。